Symposia: Hemophilia A and B: Clinical and Epidemiological
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Bleeding and Clotting, Antibody Therapy, Adult, Hemophilia, Bispecific Antibody Therapy, Clinical Practice (Health Services and Quality), Clinical Research, Pediatric, Diseases, Patient-reported outcomes, Treatment Considerations, Biological therapies, Immunology, Monoclonal Antibody Therapy, Biological Processes, Study Population, Human
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Bleeding and Clotting, Antibody Therapy, Adult, Hemophilia, Bispecific Antibody Therapy, Clinical Practice (Health Services and Quality), Clinical Research, Pediatric, Diseases, Patient-reported outcomes, Treatment Considerations, Biological therapies, Immunology, Monoclonal Antibody Therapy, Biological Processes, Study Population, Human
Monday, December 9, 2024: 10:30 AM-12:00 PM
Room 30
(San Diego Convention Center)
Moderators:
Johnny Mahlangu, MD,
and
Allison P. Wheeler, MD, ARRAY(0xf80f3f8)
Disclosures:
Wheeler: Novo Nordisk: Consultancy, Honoraria, Research Funding; Octapharma: Research Funding; Bayer: Honoraria; BioMarin: Honoraria; Bioverativ: Honoraria; CSL Behring: Honoraria; Genentech: Honoraria; HEMA Biologics: Honoraria; Octapharma USA: Honoraria; Pfizer Inc: Honoraria; Sanofi-Aventis USA: Honoraria; Shire North America: Honoraria; Spark Therapeutics: Honoraria; Takeda Pharmaceuticals: Honoraria.
This session will present the latest data on safety and efficacy of diverse novel hemostatic agents used for the prevention of bleeds in hemophilia A and B with and with inhibitors. The data on pediatric patients and long term effects of these therapies will be included.
10:30 AM
10:45 AM
11:00 AM
11:15 AM
11:30 AM
11:45 AM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH